Objective: Non-local progression is a major concern in non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). Herein we aimed to create a pre-treatment prognostic nomogram for patients with Stage I NSCLC receiving SBRT. Methods: We retrospectively studied 182 eligible patients. Patients were randomly divided into a model (70%) group and a validation (30%) group. In the model group, thirteen parameters consisting of patient, treatment, and tumor factors were studied and multivariate Cox proportional hazards regression was performed to identify independent predictors for survival outcome, based on which we developed clinical nomogram. The nomogram was externally validated in the validation group. Results: Multivariate analysis showed that tumor size (P = 0.011) was the only factor correlated with 2-year overall survival, whereas 2-year locoregional control (LRC) was significantly related to tumor size (P = 0.024) and the maximum standardized uptake value (SUV max ) (P = 0.044), so does 2-year progression-free survival (PFS) (tumor size: P = 0.026; SUV max : P = 0.038). Nomogram for 2-year LRC and 2-year PFS were created based on aforementioned results. The C-indexes for the nomograms to predict 2-year LRC and PFS were 0.816 and 0.804, respectively, in model group, and were 0.729 and 0.731, respectively, in the validation group. Calibration plots also showed that the model performed well. Conclusions: Tumor of larger size and higher SUV max predisposed patients to early onset of locoregional and distant progression. The nomogram developed in our study would be helpful in clinical decision-making and selection of patients who may benefit from more rigorous follow-up and aggressive systemic treatment plan.
Introduction
In cancer statistics 2017, lung cancer remains the most common cause of cancer death, accounting for more than one-quarter (26%) (1) . For the early-staged non-small cell lung cancer (ES-NSCLC), while lobectomy with mediastinal node dissection or sampling remains the mainstay treatment for operable patients, stereotactic body radiotherapy (SBRT) has emerged as an alternative for patients who refuse surgery or are deemed as medically inoperable. Although several studies demonstrated satisfactory result of SBRT, clinical outcome of ES-NSCLC varied a lot, indicating the heterogeneity among this group of patients, which may pose challenge in clinical counseling and decision-making.
Potential prognostic factors for NSCLC treated by SBRT have been widely studied (2) (3) (4) , however, predicting disease progression depends on the combination of a set of factors' predictive magnitude. Nomogram is one of prognostic models that can help in prognostication at the individual level. Studies have reported better performance of nomograms in prognosis prediction than the traditional staging systems (5) (6) (7) . Till today, Amsterdam Prognostic Model was the only reported nomogram model for the ES-NSCLC treated by SBRT (8) . However, that model was not feasible for recurrence prediction, which appeared to be a major concern in clinical setting (9). Besides, the maximum standardized uptake value (SUV max ) was not included in that study, while its prognostic value has been identified in many studies (2, 10, 11) .
Several reports have proposed the idea of adjuvant treatment after lung SBRT for NSCLC (12) (13) (14) . In the era of emerging immunotherapies and targeted therapies, patients with ES-NSCLC deserve to have better therapeutic approaches based on their individual situation. Therefore, accurate prognostic models for prognosis prediction will be greatly beneficial. In this study, we aim to develop clinical nomograms to predict treatment outcome of Stage I NSCLC patients treated with SBRT.
Materials and methods

Study population
The study was approved by the Zhongshan Hospital Ethics Committee, and institutional review board protocols were followed when informed consent was obtained from each patient. All patients who underwent SBRT via helical tomotherapy (HT) for primary Stage I NSCLC at our institution between January 2010 and March 2017 were retrospectively assessed for their eligibility. Lung cancer stage was classified according to the TNM seventh edition by American Joint Committee on Cancer on the basis of computed tomography (CT) imaging and positron emission tomography-CT (PET-CT). Patients were diagnosed pathologically or clinically, which was done by a multidisciplinary team composed of doctors from radiology, pulmonary, radiotherapy departments based on consecutive increase in tumor size in CT or pathological uptake of 18 F-fluorodeoxyglucose in the lesion. Staging was based on thin-section CT and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) scans. The inclusion criteria were pathologically or clinically diagnosed Stage I NSCLC based on aforementioned criteria. Patients were excluded if they have history of thoracic treatment or adjuvant chemotherapy during follow-up. For each patient, patient related variables, tumor related variables, treatment and follow-up information were reviewed and recorded.
Treatment and follow-up
The technique and treatment planning used for HT-SBRT patients has been described in previous reports (15) . All patients were immobilized using body fixation and simulated by respiration-correlated four-dimensional CT (Siemens Somatom Sensation, Siemens Healthineers Corporation, Germany) with slice thickness of 3 mm. Dynamic 4D-CT scanning and Real-Time Position Management System were used to track the motion of the tumors and other internal organs during free breathing. Fractionation schemes including 6 Gy × 10 fractions for tumors that were centrally located or extensively adhered to chest wall and 10 Gy × 5 fractions for other peripheral located tumors.
All patients were followed up with chest CT, abdominal B-Ultrasound and serum tumor marker every 3 months during the first year and every 6 months thereafter. Bone emission computed tomography and brain nuclear magnetic resonance imaging were performed once a year during the follow-up. PET-CT was reserved to evaluate progressive changes on CT scans that were suspected of tumor relapse.
Overall survival (OS) was defined from the date of treatment initiation to the date of death for any causes or the date of last follow-up. Locoregional recurrence (LRC) was defined, according to the previous study, as a recurrence in the same lobe as the primary lesion and the ipsilateral hilum or mediastinum (9). Progression-free survival (PFS) was calculated as the date of treatment to the date of first recurrence, including locoregional recurrence or distant metastasis.
Identification of prognostic factors and modeling of the nomogram
Patients were randomly divided into a model group (70%) and a validation group (30%). In the former group, the Cox proportional hazards models were performed to evaluated factors potentially affecting 2-year OS, LRC and PFS. Variables considered significant (P < 0.05) in the univariate analyses were subjected to the multivariate Cox regression analysis, based on which we developed the nomogram for predicting surviving outcomes. Harrell's Concordance index (C-index) was used to evaluate the predictive accuracies for the model and the validation group. The predictive role of SUV max was assessed as a continuous variable in Cox proportional hazards models and was used as categorical variables in nomogram establishment. The receiver operating characteristic (ROC) curve analysis was applied to determine the optimal cut-off level for SUV max as a predictor of OS, LRC and PFS, respectively.
Nomogram establishment and calibration were performed using R software (version 3.3.2), and all the other statistical analyses were conducted with SPSS 24.0 (SPSS Inc., Chicago, IL, USA). A two-sided P value less than 0.05 was considered statistically significant in all tests.
Results
Descriptive statistics
A total of 182 patients were eligible for the study, and 127 patients were included in the model group and 55 in the validation group. The clinicopathlogical features of the patients in training group are shown in Table 1 . Biopsy was performed in 99 patients, and unavailable pathological confirmation was mainly due to patients' unwillingness and technical difficulties during biopsy attempt.
In the model group, after a median follow-up of 23 months, 16 patients died, among whom 14 patients were died from disease progression. The median time to any initial disease progression was 15 months. Twenty-two patients developed locoregional recurrence, and 23 patients experienced distant metastasis (4 to the brain, 4 to the bone, and 15 to the different lobe). The 2-year LRC, PFS and OS were 80.7%, 75.3% and 84.7%, respectively. In the validation group, the median follow-up was 20.5 months, and the 2-year LRC, PFS and OS were 74.2%, 70.7% and 90.3%, respectively.
Univariate and multivariate analyses for OS, LRC and PFS
A total of 13 variables of clinical interest were included in the Cox regression analysis. Univariate and multivariate analysis are shown in Table 2 . Tumor size (HR = 2.220, P = 0.011) was the only independent prognostic factor for 2-year OS, whereas both tumor size and SUV max showed significant association with 2-year LRC (tumor size: HR = 1.891, P = 0.024; SUV max : HR = 1.069, P = 0.044) and PFS (tumor size: HR = 1.681, P = 0.026; SUV max : HR = 1. 059, P = 0.038).
Establishment and validation of the nomograms for 2-year LRC and PFS
Considering that the 2-year LRC and PFS have more than one clinical factor significantly related, final models predicting LRC and PFS were made based on tumor size and SUV max (Fig. 1) . The ROC analyses indicated that the optimal cut-off point of the SUV max level was 8.6 for LRC (area under the ROC = 0.896; sensitivity, 95.5%; and specificity, 81.0%) and 8.6 for PFS (area under the ROC = 0.850; sensitivity, 80.6%; and specificity, 83.3%) respectively. The C-indexes for the nomograms to predict LRC and PFS were 0.816 (95% CI: 0.733-0.899) and 0.804 (95% CI: 0.725-0.883), respectively. In the validation cohort, the C-indexes for the nomograms to predict LRC and PFS were 0.729 (95% CI: 0.609-0.849) and 0.731 (95% CI: 0.619-0.843), respectively, indicating a sufficient level of accuracy. The calibration plots for the probability of 2-year LRC and PFS also demonstrated good consistence between the prediction and the observation in both model group and validation group (Fig. 2) .
According to the characteristics of the patients in model group, the nomogram is valid in the total points range between 0 and 171 for LRC and range between 0 and 179 for PFS. Therefore, patients in validation group were divided into two risk groups by total points of 85 and 90 to compare LRC and PFS, respectively. Fig. 3 shows significant distinction between LRC (P = 0.004) and PFS (0 = 0.001) within the validation group.
Discussion
To the best of our knowledge, this is the largest study addressing the use of HT-SBRT in Stage I NSCLC. What's more, the predictive nomogram developed in our study was the first one that include pre-treatment SUV max , and can be used for prediction of LRC and PFS after SBRT-treated Stage I NSCLC patients.
The excellent local tumor control and low rates of toxicity have paved the way for the wide use of SBRT in ES-NSCLC. However, non-local failure remains a clinical concern. Van et al. conducted a comparison study between Stage I NSCLC patients treated with surgery or SBRT (9). The adjusted overall survival after surgery or SBRT was not different, while surgery conferred better locoregional tumor control. Multivariable Cox-Model showed that nodal and distant metastases were significant independent predictive factors for survival. Several other studies also raised concern about distant metastasis (16, 17) . However, currently, there was no model available for predicting non-local progression for early-staged lung SBRT patients. We though that early recognition of patients who are at high risk of locoregional or distant failure is of great benefit for patients counseling and can help in exploring ways to improve oncologic outcomes.
Among several prediction models, nomogram is likely to be a user-friendly choice which can provide rapid and accurate prognostic information compared to otherwise complex statistical estimates. Our LRC and PFS prognostication models for Stage I NSCLC treated by SBRT were based on tumor size and SUV max , and were validated in another separate patient group. The prediction ability was supported by both C-index and the calibration plots.
Previously, Louie published the only nomogram applicable for OS prediction in ES-NSCLC treated with SBRT (8) . Different from Amsterdam Prognostic Model, our model focused on LRC and PFS prediction, and included SUV max , which was overlooked in Amsterdam Prognostic Model. 18 F-FDG PET/CT is commonly performed in diagnosis and staging of lung SBRT patients, and has been shown to have important prognostic value in several studies (13, (18) (19) (20) . We thought that the relationship between increased SUV max and rapid onset of locoregional or distant failure could be interpreted in mainly two ways. Firstly, biologically speaking, primary tumor FDG avidity incorporated information about metabolic activity. Studies showed that tumor aggressiveness defined by an increased Ki-67 is correlated with SUV max but not with TNM stage (21) (22) (23) . Besides, SUV max was also reported to correlated to tumor histology, vascular endothelial growth factor (VEGF) expression, epidermal growth factor receptor (EGFR) mutations and other bioinformation, thus might be a gross marker of metastatic potential (24) (25) (26) . Secondly, some studies have raised concern about occult nodal involvement in SBRT-treated NSCLC and suggested its association with SUV max of primary tumor (27, 28) . Clinically, because of old age or comorbidities, a large number of patients with ES-NSCLC receiving SBRT were inoperable, for whom FDG-PET/CT scan was the main tool for nodal staging, where small lymph node metastases were likely to be missed. A proportion of 20-30% of clinical Stage I NSCLC were reported to be upstaged by finding positive lymph nodes (29) . Due to these, inclusion of SUV max could bring increased discrimination and precision of the model. Several other studies also reported prediction models of survival outcome for NSCLC. Zhou et al. found that the support vector machine with the clonal selection algorithm optimal parameter set selection strategy performed best in predicting distant failure in lung SBRT patients (30) . However, such model did not provide accurate prediction of patients' survival. Liu investigated tumor control probability for SBRT of early-stage lung cancer using different bio-physical models (31) . That study was mainly based on radiobiological effects, while other tumor characteristics were not considered. Our study was more comparable to that reported by Yang et al. (32) , who developed a recurrence risk-scoring model based on tumor size, SUV max and lymphovascular invasion (LVI). Covariates such as LVI, visceral pleural involvement or extent of surgery, was reported to influence the outcome after surgery (33, 34) , but was not available for SBRT patients.
The clinical relevance of our nomogram lies in two aspects. On the one hand, it was demonstrated in some studies that there is no statistically significant difference regarding treatment outcomes between operable and inoperable NSCLC patients treated by SBRT (35, 36) , which indicated that our model can be used for both operable and inoperable patients. Clinically, some operable Stage I NSCLC patients hesitate between surgery and SBRT, in such a circumstance, our model can serve as a reference for decision-making. On the other hand, regional and distant progression are major concern after SBRT, early recognition of patients at high risk of disease progression may help in tailoring treatment method based on individual condition. The role of adjuvant treatment after surgery has been studied extensively (37, 38) , while data concerning the role of adjuvant treatment after SBRT was rare, which may be due to the older age and frailer condition of SBRT patients. However, nowadays, more and more SBRT patients are borderline operable, or even operable and have a longer life expectancy, for whom more aggressive treatment should be considered. With the development of immunotherapies and targeted therapies, early-staged NSCLC patients deserve more personalized treatment option. Several studies have proposed the idea of adjuvant treatment after lung SBRT for NSCLC tumors (12, 14) . In addition, a combination of immunotherapeutic approach and stereotactic ablative radiotherapy (SABR), known as I-SABR, has been proposed for potential benefit in eliminating micrometastasis (39, 40) . As a matter of fact, there is also a clinical trial comparing I-SABR versus SABR alone for Stage I, selected Stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer (NCT03110978). There is a room for us to improve treatment method for early staged NSCLC, and our models might be useful for future clinical trial design, such as eligibility screening and patients' stratification.
Despite of the clinical application of our model, the present study still have some limitations. Firstly, this is a single center based study, result from a multi-center research with a larger number of patients are wanted. Secondly, we mainly focused on 2-year outcomes after the treatment, a longer follow-up time was needed for more accurate results. What's more, the performance of our nomogram could be improved by including additional variables. For example, pretreatment CT features (41), post-SBRT positron emission tomography (PET) (42) , and laboratory findings (43) has been suggested to have prognostic implication in early-stage NSCLC, further work is required to verify these variables and to explore its incorporation in the prediction model.
In spite of these limitations, our study proposed the first nomograms for accurate prediction of 2-year LRC and PFS for SBRTtreated Stage I NSCLC. The model will be useful in clinical consulting and decision-making. Risk stratification by the nomograms could identify patients at high risk of regional or distant metastasis and might be helpful for future clinical trial. 
